Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InspireMDSTU:II2 -1.65%47 Debt-to-Equity is 0.07 as of Mar. 2026, which is at its 10-year median of 0.07. GuruFocus rates STU:II2 with a GF Score™ of 47/100 and a GF Value™ of €1.53 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 705 Medical Devices & Instruments companies, InspireMD ranks better than 74.89% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for InspireMD's Debt-to-Equity or its related term are showing as below:
STU:II2'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.77 Med: 0.07 Max: 0.66
Current: 0.07
During the past 13 years, the highest Debt-to-Equity Ratio of InspireMD was 0.66. The lowest was -0.77. And the median was 0.07.
STU:II2's Debt-to-Equity is ranked better than 74.89% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs STU:II2: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
InspireMD Debt-to-Equity Related Terms
InspireMD Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for InspireMD's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:II2 vs TELA, BDMD, PAVM: Debt-to-Equity Comparison
For the Medical Devices subindustry, InspireMD's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where InspireMD's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InspireMD (STU:II2) has a Debt-to-Equity of 0.07 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on InspireMD and its competitors. This is near median its historical median of 0.07. According to the industry distribution chart, InspireMD ranks #177 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 25.1%.
Is InspireMD's Debt-to-Equity too high?
InspireMD's current Debt-to-Equity of 0.07 is near median its 10-year median of 0.07. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. InspireMD's value of 0.07 is 69.6% below this industry median. Based on the distribution chart, InspireMD ranks #177 out of 705 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, InspireMD has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Debt-to-Equity compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #177 out of 705 companies for Debt-to-Equity. This puts InspireMD in the upper half of its industry. The industry median Debt-to-Equity is 0.23. InspireMD's value of 0.07 is 69.6% below this benchmark. While the company's 10-year median is 0.07 vs. the industry median of 0.23, InspireMD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InspireMD's current Debt-to-Equity of 0.07 is 69.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on InspireMD and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current Debt-to-Equity is 0.07, which is near median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.53, compared to a current price of €0.60 — trading 61.1% below its estimated fair value. The current Debt-to-Equity is 0.07, which is near median its 10-year median of 0.07 and 69.6% below the Medical Devices & Instruments industry median of 0.23. InspireMD's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For InspireMD (STU:II2), the current Debt-to-Equity is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (STU:II2) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of €0.60 is trading 61.1% below its estimated GF Value™ of €1.53.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for STU:II2:
Debt-to-Equity: 0.07 (near median its 10-year median of 0.07)
GF Value™: €1.53 vs. price of €0.60 (61.1% below fair value)
Industry Position: 69.6% below the Medical Devices & Instruments median (#177 of 705)
No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
47GF Score
Get the complete analysis for STU:II2
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:II2 has been successfully added to your 
